During the corresponding time, Autolus Therapeutics Plc recorded a revenue increase by 118.37 % year on year, sequentially revenue grew by 74.27 %. While revenue at the Autolus Therapeutics Plc's corporate clients
Autolus Therapeutics Plc's Comment on Sales, Marketing and Customers
The company's customers primarily operate in the healthcare sector, including federal programs, healthcare benefit programs, private third-party payors, healthcare providers, health plans, and healthcare clearinghouses. This group encompasses physicians such as doctors, dentists, optometrists, podiatrists, and chiropractors, as well as other healthcare providers like physician assistants and nurse practitioners, and teaching hospitals. Additionally, the company serves manufacturers of drugs, devices, biologics, and medical supplies that receive payments under Medicare, Medicaid, or the Children’s Health Insurance Program. These entities are subject to various U.S. federal laws and regulations concerning healthcare fraud, privacy, security, and reporting requirements.
Autolus Therapeutics has recently announced the FDA approval of AUCATZYL (obecabtagene autoleucel or obe-cel) for the treatment of adults suffering from relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This pivotal decision follows a recognized need for more effective treatment options for a patient population with historically poor prognosis. The approval is not only a significant milestone for Autolus Therapeutics but also represents a transformative moment in the field of hematologic oncology. B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive form of blood cancer characterized by rapid proliferation of immature B cells, which often leads to severe complications and hi...
The recent advances in B-ALL research were vividly highlighted at the American Society of Clinical Oncology (ASCO), where a Pivotal Phase 2 FELIX study s longer-term follow-up and additional data analysis for obe-cel were selected for oral presentation. The researchers conducted this study to treat adults with relapsed/refractory B-ALL (r/r B-ALL), proclaiming significant revelations in this field.The ASCO meeting served as a knowledge sharing platform, offering updated insights from the FELIX study that could potentially propel game-changing therapeutic interventions in r/r B-ALL. The comprehensive analysis of the Phase 2 FELIX study’s subsequent developments and inherent data were important for shaping t...
Autolus Therapeutics, a leading clinical-stage biopharmaceutical company specializing in the development of innovative immunotherapies for cancer treatment, has successfully obtained the prestigious certification from the Medicines and Healthcare products Regulatory Agency (MHRA) for its Nucleus commercial manufacturing site. This significant achievement highlights the company s commitment to maintaining world-class production standards and bolstering its position in the global pharmaceutical market.Deteriorating Revenue Amidst Regulatory Milestone:While Autolus Therapeutics celebrates its milestone certification, it faces challenges on the financial front. The company witnessed a substantial decline in reve...
Autolus Therapeutics Plc’s Comment on Sales, Marketing and Customers
The company's customers primarily operate in the healthcare sector, including federal programs, healthcare benefit programs, private third-party payors, healthcare providers, health plans, and healthcare clearinghouses. This group encompasses physicians such as doctors, dentists, optometrists, podiatrists, and chiropractors, as well as other healthcare providers like physician assistants and nurse practitioners, and teaching hospitals. Additionally, the company serves manufacturers of drugs, devices, biologics, and medical supplies that receive payments under Medicare, Medicaid, or the Children’s Health Insurance Program. These entities are subject to various U.S. federal laws and regulations concerning healthcare fraud, privacy, security, and reporting requirements.
Sources:
Autolus Therapeutics Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Autolus Therapeutics Plc’s corporate clients.
For your research, we’ve provided 9 tables on Autolus Therapeutics Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
157.35 %